TRCT
PAVM icon

Tower Research Capital (TRC)’s PAVmed PAVM Stock Holding History

Tower Research Capital (TRC)’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-622
Closed -$6.31K – 5531
2026
Q1 		$6.31K Buy
622
+476
+326% +$4.5K ﹤0.01% 4062
2025
Q4 		$964 Hold
146
– – ﹤0.01% 4787
2025
Q3 		$1.89K Sell
146
-4
-3% -$59 ﹤0.01% 4715
2025
Q2 		$2.69K Hold
150
– – ﹤0.01% 4605
2025
Q1 		$3.25K Sell
150
-1
-0.7% -$21 ﹤0.01% 4446
2024
Q4 		$2.84K Buy
151
+27
+22% +$798 ﹤0.01% 4765
2024
Q3 		$4.57K Sell
124
-199
-62% -$6.1K ﹤0.01% 4499
2024
Q2 		$7.91K Buy
323
+241
+294% +$12K ﹤0.01% 4412
2024
Q1 		$5.26K Sell
82
-44
-35% -$3.33K ﹤0.01% 4567
2023
Q4 		$15.5K Buy
126
+11
+10% +$1.3K ﹤0.01% 3821
2023
Q3 		$15.3K Buy
115
+58
+102% +$8.99K ﹤0.01% 3625
2023
Q2 		$10.4K Sell
57
-27
-32% -$5.4K ﹤0.01% 4120
2023
Q1 		$14K Buy
84
+45
+115% +$9.47K ﹤0.01% 3903
2022
Q4 		$9K Sell
39
-15
-28% -$5.66K ﹤0.01% 4235
2022
Q3 		$21K Buy
+54
New +$30.6K ﹤0.01% 3900
2022
Q2 		– Sell
-50
Closed -$24.2K – 6409
2022
Q1 		$29K Buy
50
+17
+52% +$12.6K ﹤0.01% 3194
2021
Q4 		$36K Buy
33
+23
+230% +$50K ﹤0.01% 3052
2021
Q3 		$38K Sell
10
-2
-17% -$6.31K ﹤0.01% 3181
2021
Q2 		$34K Sell
12
-52
-81% -$123K ﹤0.01% 3356
2021
Q1 		$127K Buy
64
+41
+178% +$61.7K ﹤0.01% 2392
2020
Q4 		$22K Sell
23
-54
-70% -$46.2K ﹤0.01% 3809
2020
Q3 		$62K Buy
77
+22
+40% +$19.6K ﹤0.01% 3445
2020
Q2 		$53K Buy
+55
New +$55K ﹤0.01% 2998
2017
Q2 		– Sell
-2
Closed -$5K – 3240
2017
Q1 		$5K Hold
2
– – ﹤0.01% 2213
2016
Q4 		$5K Buy
2
+1
+100% +$4.19K ﹤0.01% 3051
2016
Q3 		$3K Buy
+1
New +$6.36K ﹤0.01% 2875

Other funds holding PAVM

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s PAVM Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of PAVmed (PAVM) in Q2 2026, closing a stake of 622 shares — an estimated $6.31K sold.

Tower Research Capital (TRC) first reported a position in PAVM in Q3 2016 and held it in 26 quarters. The position peaked at $127K in Q1 2021. 19 funds tracked by Wall St. Rank hold PAVM as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining PAVmed position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 622 PAVmed shares in Q2 2026, an estimated $6.31K.
  • Tower Research Capital (TRC) first reported a position in PAVmed in Q3 2016 and held it in 26 quarters.
  • Tower Research Capital (TRC)'s PAVmed position peaked at $127K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held PAVmed as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.